Filing Details
- Accession Number:
- 0001209191-19-006736
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-04 15:53:34
- Reporting Period:
- 2019-01-31
- Accepted Time:
- 2019-02-04 15:53:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1358762 | Reata Pharmaceuticals Inc | RETA | Pharmaceutical Preparations (2834) | 113651945 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1662395 | Douglas Jason Wilson | 2801 Gateway Drive Suite 150 Irving TX 75063 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2019-01-31 | 6,135 | $0.00 | 6,135 | No | 4 | C | Direct | |
| Class A Common Stock | Disposition | 2019-01-31 | 6,135 | $80.00 | 0 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2019-02-01 | 865 | $0.00 | 865 | No | 4 | C | Direct | |
| Class A Common Stock | Disposition | 2019-02-01 | 865 | $80.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | S | Direct | |
| No | 4 | C | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Class B common stock | Disposition | 2019-01-31 | 6,135 | $0.00 | 6,135 | $0.00 |
| Class A Common Stock | Class B common stock | Disposition | 2019-02-01 | 865 | $0.00 | 865 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 47,511 | No | 4 | C | Direct | ||
| 46,646 | No | 4 | C | Direct |
Footnotes
- The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 26,2018.
- The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
Billionaire Hedge Funds
